Background Human malignant melanoma is a highly aggressive, heterogeneous and drug-resistant cancer. Due to a high number of clones, harboring various mutations that affect key pathways, there is an exceptional level of phenotypic variation and intratumor heterogeneity (ITH) in melanoma. This poses a significant challenge to personalized cancer medicine. Hitherto, it remains unclear to what extent the heterogeneity of melanoma affects the immune microenvironment. Herein, we explore the interaction between the tumor heterogeneity and the host immune response in a melanoma cohort utilizing The Cancer Genome Atlas (TCGA). Methods Clonal Heterogeneity Analysis Tool (CHAT) was used to estimate intratumor heterogeneity, and immune cell com...
Immunotherapy prolongs survival in only a subset of melanoma patients, highlighting the need to bett...
In this study, we incorporate analyses of genome-wide sequence and structural alterations with pre- ...
Immunotherapy prolongs survival in only a subset of melanoma patients, highlighting the need to bett...
Because immune checkpoint inhibitors (ICIs) are effective for a subset of melanoma patients, identif...
Background: Clinical response to MAPK inhibitors in metastatic melanoma patients is heterogeneous fo...
Background:Clinical response to MAPK inhibitors in metastatic melanoma patients is heterogeneous for...
Melanoma is a cancer that exhibits one of the most aggressive and heterogeneous features. The incide...
There is growing evidence that tumour heterogeneity has an imperative role in cancer development, ev...
Background Tertiary lymphoid structures (TLSs) are immune aggregates in peripheral tissues that may ...
Immune checkpoint inhibitors (ICIs) have demonstrated impressive antitumor activity in patients with...
Cellular heterogeneity is regarded as a major factor for treatment response and resistance in a vari...
Background Skin melanoma is a highly immunogenic cancer. The intratumoral immune cytolytic activity ...
Background: Immune infiltration of the tumor microenvironment has been associated with improved surv...
Melanoma is one of the most immunogenic tumors and its relationship with host immune system is curre...
A prospective study explored the heterogeneous nature of metastatic melanoma using Multiplex immunoh...
Immunotherapy prolongs survival in only a subset of melanoma patients, highlighting the need to bett...
In this study, we incorporate analyses of genome-wide sequence and structural alterations with pre- ...
Immunotherapy prolongs survival in only a subset of melanoma patients, highlighting the need to bett...
Because immune checkpoint inhibitors (ICIs) are effective for a subset of melanoma patients, identif...
Background: Clinical response to MAPK inhibitors in metastatic melanoma patients is heterogeneous fo...
Background:Clinical response to MAPK inhibitors in metastatic melanoma patients is heterogeneous for...
Melanoma is a cancer that exhibits one of the most aggressive and heterogeneous features. The incide...
There is growing evidence that tumour heterogeneity has an imperative role in cancer development, ev...
Background Tertiary lymphoid structures (TLSs) are immune aggregates in peripheral tissues that may ...
Immune checkpoint inhibitors (ICIs) have demonstrated impressive antitumor activity in patients with...
Cellular heterogeneity is regarded as a major factor for treatment response and resistance in a vari...
Background Skin melanoma is a highly immunogenic cancer. The intratumoral immune cytolytic activity ...
Background: Immune infiltration of the tumor microenvironment has been associated with improved surv...
Melanoma is one of the most immunogenic tumors and its relationship with host immune system is curre...
A prospective study explored the heterogeneous nature of metastatic melanoma using Multiplex immunoh...
Immunotherapy prolongs survival in only a subset of melanoma patients, highlighting the need to bett...
In this study, we incorporate analyses of genome-wide sequence and structural alterations with pre- ...
Immunotherapy prolongs survival in only a subset of melanoma patients, highlighting the need to bett...